Faron Pharmaceuticals Oy (LON:FARN) Stock Price Passes Below 50-Day Moving Average – Here’s Why

Faron Pharmaceuticals Oy (LON:FARN) passed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of GBX 181.52 and traded as low as GBX 171. Faron Pharmaceuticals Oy shares last traded at GBX 174, with a volume of 3,397 shares.

Faron Pharmaceuticals Oy Stock Up 0.9%

The company has a debt-to-equity ratio of 922.55, a current ratio of 1.45 and a quick ratio of 1.09. The stock has a market capitalization of £199.09 million, a PE ratio of -6.44 and a beta of 0.36. The company has a 50 day moving average price of GBX 181.52 and a 200-day moving average price of GBX 191.30.

Insider Transactions at Faron Pharmaceuticals Oy

In other Faron Pharmaceuticals Oy news, insider Jurriaan Dekkers sold 4,000 shares of the company’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of GBX 182, for a total value of £7,280. Insiders own 4.05% of the company’s stock.

About Faron Pharmaceuticals Oy

Faron (AIM: FARN, First North: FARON) is a clinical stage biopharmaceutical company developing novel treatments for medical conditions with significant unmet needs. The Company currently has a pipeline based on the receptors involved in regulation of immune response in oncology and organ damage. Clevegen (bexmarilimab), its investigative precision immunotherapy, is a novel anti-Clever-1 antibody with the ability to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development.